Rollover Equity and Earnouts in a DSO Deal: What You’re Really Buying

An owner sent me a letter of intent last spring with one line highlighted in yellow. The headline number.

She had read the rest twice. Twice.

She still could not tell me what most of it meant, and she is a careful, numerate dentist who runs a tight ship and reads her own profit-and-loss statement every month without an accountant hovering nearby.

Roughly a third of what she was being offered was not money. It was two promises, drafted in the vocabulary of a partnership agreement nobody had shown her yet.

Cash at close is a number. You count it, bank it, pay tax on it, and it stops being anybody else’s decision.

Rollover equity and an earnout are claims. Conditional, illiquid, settled years later by people who will be running your operatory instead of you.

What are you actually buying when part of the price is rollover equity and an earnout? A claim, not cash.

Rollover equity is ownership in the buyer’s company that pays at a future liquidity event and usually ranks below the sponsor’s capital. An earnout is money paid later, only if a metric the buyer largely controls hits an agreed target.

Key takeaways

• Rollover equity and earnouts are legitimate, standard structures, used across almost every affiliating organization in dentistry. The question is never whether to accept one. It is what the specific one in front of you is worth.
• Where the equity sits decides how it behaves. Ownership in your own practice entity and ownership in the parent company are different instruments with different risks, and the letter of intent frequently does not say which you are getting.
• What ranks above your equity decides what it pays. Common equity underneath a preferred stack can be worth nothing in an outcome that still looks like a successful sale from the outside.
• The earnout metric is worth more than the earnout percentage. The same practice, in the same year, can earn the full amount or nothing at all depending on two definitions in the agreement.
• Competition negotiates the proportions, not just the price. With one bidder you take the structure offered. With four, the split between cash, equity and earnout becomes a live term.

Why buyers build deals this way at all

Give the structure its due first, because the cynical reading of it is wrong, and an owner who walks into the room assuming the equity is a trick will negotiate the wrong terms and lose money doing it.

A DSO is a dental support organization: the management company owns the non-clinical side of a practice and handles everything outside the operatory, while a licensed dentist keeps ownership of the clinical entity.

That split is not cosmetic. Most states restrict who may own or control a practice under the corporate practice of dentistry doctrine, and the structure exists to operate inside those rules.

An organization buying your practice inherits two genuine problems on the day it signs.

The first is that most of what it is paying for walks out of the building at five o’clock: patient loyalty, referral habits, the hygienist who has cleaned the teeth of three generations in one family, your own case acceptance rate.

The second is capital. Acquiring at scale in a sector completing well over 200 affiliations a year devours an extraordinary amount of it, and every dollar wired at closing is a dollar unavailable for the next practice down the road.

Rollover equity solves both at once. It means keeping a slice of ownership in the buyer’s company instead of taking all cash at close.

It also achieves something no employment agreement ever manages, which is to give a selling dentist a reason to care about year three, long after the novelty of the wire transfer has worn off entirely.

An earnout is part of the price paid later, only if the practice hits agreed targets after closing.

It bridges the gap between what you believe the practice will do and what a buyer will underwrite before watching you for a year.

Both are honest answers to awkward problems. I have watched rolled paper turn out to be the smartest thing an owner signed.

None of that makes it free, and none of it makes it equivalent to cash.

The arithmetic we will use

Numbers make this decidable. So here is a single practice carried right through the article, built from the kind of figures I see monthly, and illustrative rather than anybody’s actual terms.

Two locations. General dentistry.

Collections of $4.4 million, with overhead running near 60 percent, which is respectable for a group that size.

Now the bridge. Most dentists never build it properly, and I would put the resulting confusion at the top of any honest list of the expensive gaps in dental deal literacy.

Collections minus true operating overhead leaves about $1.76 million. Subtract what it would cost to hire an associate at market rate to produce what the owner produces herself, call it $560,000.

What survives is roughly $1.2 million of adjusted EBITDA: pure operating profit after paying a market-rate dentist to do the work you currently do yourself.

That figure is what a buyer values. Not collections, and emphatically not a “percentage of collections” number somebody quoted at a study club.

At a multiple of 8, the headline reads $9.6 million. Every organization prices differently and none publish a price sheet, so treat the multiple as scaffolding rather than a forecast.

Our guide to dental practice EBITDA multiples covers the ranges by size and buyer type.

The offer arrives split 65 percent cash at close, 20 percent rollover equity, 15 percent earnout.

Which means $6.24 million of certain money, $1.92 million of paper, and $1.44 million that may never exist. A third of the headline is hypothetical.

Where does the rollover equity actually sit?

I ask this first. Every time.

And the letter of intent frequently cannot answer it, which tells you something about how rarely owners ask.

Rolled paper generally lives in one of two places. Ownership in the entity holding your own practice, sometimes labelled joint-venture or subsidiary equity.

Or ownership in the parent company perched above every location the organization runs.

Owners hear the word “equity” and picture the second while being handed the first. Or the reverse.

They behave nothing alike.

	Equity in your practice entity	Equity in the parent company
What its value tracks	Your two locations only	Every location the organization owns
Who influences performance	Largely you, day to day	Executives you will rarely meet
How it typically pays	Distributions of practice cash flow, plus a share of any later sale of that entity	A future recapitalization or sale of the whole platform
What usually ranks above it	Practice-level debt and any management fee	Platform debt, then the sponsor’s preferred capital
Typical volatility	Lower ceiling, higher floor	Higher ceiling, and a floor that can be zero
How it gets valued	A formula in the operating agreement, often a multiple of the entity’s own earnings	Whatever the next transaction says it is worth
What a bad year elsewhere does	Nothing	Everything

Neither column is the good one. They suit different owners.

A dentist who intends to keep building, and who trusts her own hands more than anybody’s spreadsheet, usually prefers the left column, while a dentist betting on the organization’s growth story and comfortable with losing that bet wants the right.

What you cannot do is choose blind.

Ask for the name of the entity issuing your units, then ask exactly where that entity sits in the ownership chart, and keep asking until somebody draws it for you on paper.

What ranks above your equity, and what that does

Here is the part that surprises owners most, and the reason I would not sign a rollover without a lawyer who has read the specific agreement.

Sponsor capital in these platforms is rarely plain common ownership. It typically arrives as preferred capital, meaning it is repaid first, and frequently with an accrual on top that compounds quietly for as long as the money sits there.

Rolled doctor equity generally sits underneath that. So do the management incentive units.

Work it through with our practice. Suppose the parent is worth $700 million on the day you affiliate, carrying $250 million of debt, so the equity is worth $450 million on paper.

Above you sits $400 million of preferred capital with a 1x preference and an 8 percent accrual that compounds. Beneath it, the common pool is worth about $50 million, so your $1.92 million buys a shade under 4 percent of it.

Four years pass.

The preferred claim has grown to roughly $544 million, because that is simply what an 8 percent compounding accrual does to $400 million over four years while everybody is busy running practices.

The good outcome. The platform sells at a $1.05 billion enterprise value. After debt, equity is worth $800 million, the preferred takes its $544 million, and $256 million flows to common.

Your slice comes to nearly $9.8 million on a $1.92 million roll. Life-changing.

That is precisely why owners take these deals, and they are right to.

The ordinary outcome. The platform sells at $750 million, which is more than it was worth the day you joined. Equity is worth $500 million after debt, the preferred claim stands at $544 million, and nothing remains.

Your paper returns zero, on a transaction the press release will call a success.

Read those two together and the shape of the thing becomes clear. The break points are not where instinct puts them.

Run the same waterfall backwards and you get the two numbers that actually matter. The platform has to reach about $794 million in enterprise value, roughly 13 percent above where it stood when you signed, before your equity is worth a single dollar.

And it has to reach about $844 million, call it 21 percent of growth, before your equity is merely worth what it was on the day you handed it over.

Twenty-one percent of growth just to break even. That is the number nobody puts in a pitch deck, and it is calculable in about four minutes from three facts you are entitled to ask for.

None of this makes preferred capital sinister. It is how nearly every sponsored platform in American healthcare is financed, and the sponsor took real risk putting the money in.

The point is narrower. “20 percent of the deal in equity” and “$1.92 million” are not the same statement, and only one of them is reliably true.

This article is general information, not investment or legal advice. Rollover equity terms, and the tax treatment of rolled units, should be reviewed by an attorney and a CPA who work on these transactions regularly, before you sign anything.

When does rolled equity actually pay?

Equity in a sponsored platform is generally illiquid until the sponsor sells or refinances. That event is the recapitalization, and it is the whole engine of the second-bite story.

You do not control the timing.

You often cannot sell your units without permission either, and the agreement may let the company buy you out on a formula rather than at market value if you leave before the event.

The 2026 picture here has changed, and it argues for asking harder questions rather than fewer.

A large majority of DSOs have been reporting an expected recapitalization inside a one-to-three-year horizon, and 69 percent said in 2026 that their sponsors expect increased acquisition activity. Sentiment is genuinely improving.

At the same time, PitchBook’s coverage describes dental exits as difficult, with a meaningful share of platforms sitting five, seven or more years into a hold period underwritten as shorter.

Becker’s has reported directly on why some organizations have failed to recapitalize at all.

Group Dentistry Now put the practical result plainly. Dentists who rolled equity expecting a second transaction in three to five years are waiting, while sponsors wait for a return that justifies selling.

So anticipation is not a commitment. A recapitalization horizon quoted to you in a meeting is a forecast about a market, made by someone with an interest in your signature.

One case removes the clock entirely.

A platform with no private equity sponsor has no recapitalization to sell into. Rolled equity there pays through distributions of operating cash flow and an internal redemption mechanism instead of a future mark.

Different instrument, different risks. We walk through it in our piece on a dentist-owned platform with no planned exit.

Either way, the question is the same. How does this paper turn into money, and what has to be true for that to happen?

How earnouts are measured, and why the metric decides the money

Now the $1.44 million.

Earnouts in dental deals typically run 12 to 36 months and pay against a defined financial target.

Owners fixate on the percentage of the deal held in earnout, when the definition of the target is the thing that actually decides whether any of that money ever reaches them.

Say the earnout pays in full if the measured metric over the 12 months after closing at least matches the trailing 12 months at closing, reduces dollar for dollar below that, and pays nothing below 90 percent.

Trailing 12 at closing: production $4.75 million, collections $4.4 million, adjusted EBITDA $1.2 million.

Year one after closing, the practice does the same dentistry with the same team. Two things happen anyway.

The buyer adds the practice to two additional PPO plans to fill open chair time. Production rises about 4 percent, collections about 2.5 percent, and the additional write-offs push EBITDA down about 5 percent, to $1.14 million.

The buyer also charges a management fee of 4 percent of collections, roughly $180,000, which is entirely normal and appears in almost every one of these structures.

Same practice. Same year.

Four different answers.

Earnout measured on	Year-one result	Earnout paid
Production	Up about 4%	$1,440,000 (full)
Collections	Up about 2.5%	$1,440,000 (full)
EBITDA, management fee excluded	Down about 5%	$1,368,000
EBITDA, management fee included	Down about 20%	$0

A swing of $1.44 million, on identical clinical performance, decided by two sentences in a document.

That is not a buyer behaving badly. Every one of those four measurements is defensible, and an organization proposing the fourth is not cheating you.

It simply means the phrase “15 percent earnout” carries almost no information by itself.

So the questions turn specific. Which metric, defined how, calculated on which accounting methodology, and does it match the methodology used to compute EBITDA at closing?

Then the control questions, which matter more. Who sets the fee schedule and the payer mix during the measurement period?

Are parent-company allocations, management fees and shared-service charges excluded? What happens to the target if the buyer changes hours, adds a location, moves hygiene, or hires an associate on different terms?

And one that owners almost never think to ask. If the practice or the platform is sold during the earnout period, does the remaining earnout accelerate, or does it evaporate?

You also want a right to see the books behind the calculation and a named dispute mechanism. An earnout you cannot audit is a gift you have agreed to be grateful for.

The questions that decide the answer

Take this list to the meeting. Ask them in this order, and write down the answers rather than the impressions.

On the equity itself. What entity issues my units, and where does it sit in the ownership chart? Am I buying into my practice or into the parent?

On the stack. What ranks above my units, how much of it is there, and does it accrue? At what enterprise value does common equity begin to receive proceeds?

On the price. How are my units valued at issue, and how often is that recalculated? Who performs the valuation?

On liquidity. What is the expected path to a liquidity event, and what has this sponsor’s history been? What happens to my units if I retire, become disabled, or leave before that event?

On the earnout. What exactly is the metric, and does its calculation match the closing EBITDA calculation? Which costs are excluded?

Who controls the inputs?

On the downside. What happens to my equity and my earnout if the platform is recapitalized at a flat valuation, or sold to another sponsor, or restructured?

On the tax. Is my rollover structured to defer gain, or will I owe tax on paper I cannot sell? Is any of it treated as compensation for services rather than as sale proceeds?

That last one deserves its own sentence. The IRS treats a sale of assets and an exchange of ownership interests very differently.

Rolled units that vest against continued employment can land under the rules for property received for services rather than the rules for a sale.

I have seen an owner discover after closing that a slice of the deal she thought was capital gain was ordinary income. It is a solvable problem, entirely, and only before signing.

What changes when more than one buyer is bidding

Owners ask me whether they can negotiate a rollover percentage down. Almost always the honest answer is that it depends on something other than how well they argue.

A buyer approaching you directly is competing with nobody.

The structure they propose is therefore the structure they happen to prefer, and there is no reason on earth for a rational organization to propose anything else in that situation.

Put the same organization in a room with three others who also want your practice, and the conversation changes. Not because the first proposal was dishonest.

The leverage moved.

Here is what that is worth in the practice we have been carrying. Same $9.6 million headline, restructured to 80 percent cash, 10 percent equity, 10 percent earnout.

Cash at close goes from $6.24 million to $7.68 million. That is $1.44 million of certain money, moved out of two claims and into your account on closing day, with no change to the headline number at all.

Whether that trade suits you is genuinely open. An owner who believes the growth story should want more paper, not less.

The point is that the mix is a term. And a term becomes negotiable only when somebody else is bidding.

The pool is deep enough to make that real. The ADSO alone counts more than 80 member organizations, and roughly 30 to 35 acquire independent general practices at meaningful scale.

Most owners have heard of four.

Creating that comparison is what the Elite Selling System exists to do. We hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people.

Then we run a private competitive window inside that group.

With a structured offer this matters more than usual. A competitive process is the only way to see several shapes of deal side by side, and shape is what you are actually choosing between.

What to do next

If a structured offer is in front of you, do not start by deciding whether the number is good. Start by converting it into something comparable.

Document your adjusted EBITDA honestly, with the owner-production adjustment done properly. If you are not there yet, our guide to what your dental practice is worth walks through the bridge.

Then split the offer into its three parts and value each on its own terms. Certain money at close.

Paper, valued against the stack above it and the road to liquidity. Contingent money, valued against whoever controls the metric.

Ask the questions above before you are emotionally committed. Answers stop being negotiable roughly the moment you feel you have decided.

The shape of the process, and where leverage sits inside it, is covered in our overview of selling a dental practice.

Rolled equity can be the best thing in a deal. I have watched it roughly double what an owner eventually took home, and I have also watched it come to nothing while every person involved described the outcome as a win.

The difference between those two is not luck. It is three structural facts and a document, and you are entitled to all four before you sign.

We will give you that assessment free and in confidence, including the answer that you should wait and fix two things first when that is the honest one. It starts with a free, confidential practice value estimate.

Our fee varies depending on the value of the practice and is entirely success-based. If we do not get you a result, we do not get paid.

---

Frequently asked questions

What is rollover equity in a dental practice sale?

It means keeping a slice of ownership in the buyer’s company instead of taking all cash at close. Its value depends on which entity issued it, what capital ranks above it, and when a liquidity event realistically arrives.

Is rollover equity in a DSO deal a good thing?

Both outcomes are common. Equity in a platform that grows and sells well can pay more than the cash portion of the deal.

Common equity sitting under a large preferred stack can return zero in a sale that still looks successful.

Where does my rollover equity sit, in my practice or in the parent company?

Either, and the letter of intent frequently does not say. Practice-entity equity tracks your locations and usually pays through distributions.

Parent equity tracks the whole platform and pays at a recapitalization. Ask which entity issues your units.

What is a liquidation preference and why does it matter to me?

It is the right of the sponsor’s capital to be repaid before common equity receives anything, often with an accrual that compounds while it waits. It sets the enterprise value the platform must reach before your units are worth a dollar.

When does rollover equity in a DSO actually pay out?

Generally at a recapitalization, when the sponsor sells or refinances. Most organizations report an expected recap on a one-to-three-year horizon, but sector hold periods have run longer than underwritten.

Treat any stated horizon as a forecast, not a commitment.

How are dental earnouts measured, and which metric is best for the seller?

Usually against EBITDA, collections or production over 12 to 36 months. Collections and production are harder for a buyer to influence, so they favor the seller.

An EBITDA target should exclude management fees and parent-company allocations.

What if the buyer changes the practice and my earnout target becomes impossible?

That risk is real, and it is addressed in the drafting rather than afterwards. Negotiate protections that hold inputs steady, exclude buyer-imposed costs, adjust the target if the buyer changes payer mix or operations, and accelerate on a sale.

Should I negotiate the rollover percentage down and take more cash?

Only if more cash is what you actually want, and only when you have leverage. The mix is a negotiable term rather than a fixed policy, but it goes live when more than one qualified buyer is bidding.

---

Sources

Deal structure, rollover equity and earnout terms

1. Mandelbaum Barrett PC. “Navigating Types of Dental Transactions & the Financial Terms to Know.” mblawfirm.com
2. Mandelbaum Barrett PC. “The Four-Phase DSO Transaction Process: What to Expect When Selling a Dental Practice.” mblawfirm.com
3. Cranfill Sumner LLP. “Selling Your Dental Practice to a DSO: What to Expect Before, During, and After the Deal.” cshlaw.com
4. Nixon Peabody LLP. “Five Issues Dentists and DSOs Should Address Before Signing a Transaction,” 22 July 2026. nixonpeabody.com
5. Benesch, Friedlander, Coplan & Aronoff LLP. “Dental/DSO Industry Newsletter, May/June 2026.” beneschlaw.com
6. Holland & Knight. “Minority Deals in Healthcare Private Equity: An Evolving Opportunity for GPs and Founders,” February 2026. hklaw.com
7. US House Committee on Oversight. “Survey of State Laws Governing the Corporate Practice of Dentistry.” oversight.house.gov

Liquidity, hold periods and the recapitalization market

8. PitchBook. “Pulling Teeth: Why Dental Sector Exits Have Been Tough for PE.” pitchbook.com
9. Becker’s Dental Review. “Why Some DSOs Are Failing to Recapitalize.” beckersdental.com
10. Becker’s Dental Review. “How Private Equity Could Influence Dentistry in 2026.” beckersdental.com
11. Becker’s Dental Review. “The DSO Rebound.” beckersdental.com
12. Group Dentistry Now. “Cautious Optimism: Navigating the DSO M&A Market in 2026.” groupdentistrynow.com
13. Group Dentistry Now. “DSOs, Do Your Dentists Understand the Equity They Own?” groupdentistrynow.com

Buyer pool, deal activity and market structure

14. Association of Dental Support Organizations. “About ADSO.” theadso.org
15. Becker’s Dental Review. “200+ DSO Affiliations in 2025: State-by-State Breakdown.” beckersdental.com
16. Becker’s Dental Review. “69% of DSOs Plan to Boost Acquisitions in 2026: Report.” beckersdental.com

Tax treatment of rolled equity and deferred consideration

17. Internal Revenue Service. “Publication 541, Partnerships.” irs.gov
18. Internal Revenue Service. “Publication 544, Sales and Other Dispositions of Assets.” irs.gov
19. Internal Revenue Service. “Publication 525, Taxable and Nontaxable Income.” irs.gov

Practice ownership, affiliation and dental economics

20. ADA Health Policy Institute. “Practice Ownership Trends in Dentistry: A New Look at Old Data.” ada.org
21. ADA Health Policy Institute. “The State of the U.S. Dental Economy, Q1 2026 Update.” ada.org